SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 5, 2006--Affymetrix, Inc., (Nasdaq:AFFX) today announced that due to low fourth quarter instrument sales and delays in completing genotyping processing under a services contract, the Company now expects, based on preliminary financial data, that product and product related revenue for the fourth quarter ending December 31, 2005, will be roughly $15 million below previous guidance.
